Dorzolamide + TimololThird Party Manufacturing in India

Dorzolamide + Timolol works by decreasing elevated intraocular pressure via two distinct pharmacological mechanisms. It inhibits carbonic anhydrase II to lower bicarbonate ion secretion in the ciliary processes and blocks beta-adrenergic receptors to reduce aqueous humor production. Unlike systemic antiglaucoma agents, it minimizes widespread metabolic complications while maximizing local hypotensive action within the anterior chamber. It is highly effective and well-tolerated in patients with open-angle glaucoma.

Therapeutic Uses

• Open-Angle Glaucoma: Reduction of elevated intraocular pressure in patients who are insufficiently responsive to beta-blockers alone.
• Ocular Hypertension: Long-term management of intraocular pressure elevations to prevent progressive glaucomatous optic nerve damage.

Why Manufacturers Choose Dorzolamide + Timolol

Dorzolamide + Timolol third party manufacturing in India represents a high-margin opportunity within the ophthalmic segment due to the chronic nature of glaucoma management. Utilizing our partner facilities ensures strict compliance with WHO-GMP parameters for sterile solution processing. Partnering with a WHO-GMP compliant network minimizes validation issues and secures reproducible formulation dynamics for bulk distribution. This dual-action mechanism drives continuous clinical demand, making it a critical asset for comprehensive product portfolios.